News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supernus Pharmaceuticals (SUPN) Announces Publication Of Phase III Study (PROSPER) Results On Oxtellar XR®



2/3/2014 8:49:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company, today announced the publication of the Prospective, Randomized Study of Oxcarbazepine extended release in Subjects with Partial Epilepsy Refractory (PROSPER) data on Oxtellar XR. Results of this Phase III pivotal trial will appear in the upcoming March issue of Acta Neurologica Scandinavica, Volume 129, Issue 3, pages 143–153 and is available online at http://onlinelibrary.wiley.com/doi/10.1111/ane.12207/abstract.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES